Introduction Getting the in-licensing discount rate wrong doesn’t just misprice a single pharmaceutical or biotech deal—it can quietly reshape a company’s entire portfolio risk profile over time. Every in-licensing decision…
Introduction Due diligence (DD) in pharmaceutical licensing and M&A has always been a resource-intensive exercise. Thousands of documents - clinical data packages, IP portfolios, regulatory submissions, commercial contracts, manufacturing records,…
Why Biopharma Companies Are Switching to Internal AI-based Agentic Competitive Intelligence Systems For decades, the biopharmaceutical industry has been reliant on pharma competitive intelligence vendors for secondary research and monitoring…
Introduction Competitive intelligence has long served as a foundational pillar for strategic decision-making in the pharmaceutical industry. Yet today, the CI function stands at a critical inflection point. The evolution…
Pharma Out Licensing Challenges and How to Overcome Them Out licensing in pharma and biotech is frequently described as a value-inflection event — a moment when an asset's latent potential…
Essential Strategies for Successful Out-Licensing and Partnering in Pharma and Biotech Industry Dealmaking in the pharmaceutical and biotech industries plays a pivotal role in fostering growth and innovation. Partnering and…
Introduction In the pharmaceutical industry, information is power. Decisions on R&D, licensing, and product launches can involve investments worth millions, and relying on outdated or incomplete data is a costly…
Key Issues Biotech and Pharma Companies Must Address to Succeed in Out-Licensing Pharma and biotech out-licensing and partnering are essential growth drivers for innovative life sciences companies. Yet, despite repeated…
How to Leverage EBITDA Multiples for Accurate Pharma Company Valuations Determining the valuation of pharmaceutical and biotechnology companies is a crucial exercise to inform high-impact decisions including organic investments and…
How to Prioritize Threats in the Pharma Competitive Intelligence In today's rapidly evolving pharmaceutical landscape, companies face an overwhelming array of competitive threats. From emerging biotechs disrupting traditional therapeutic approaches…